Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Inclusion Criteria: * Health personnel who are or have been in contact with patients with disease due to SARS-COV-2 infection within the last 14 days before randomization. * Negative result for test against COVID-19. * Subjects who have given informed consent. * Men or women aged between 18 and 65 years, both included. * Subjects who have a smartphone where they can load an APP for monitoring the symptoms. Exclusion Criteria: * Subjects who are participating in another clinical trial. * Subjects who are unable to offer cooperation and/or have serious psychiatric disorders. * Subjects who are allergic to any of the compounds included into MV130. * Subjects who present contraindications to any of the components of BACMUNE (MV130). * Subjects who are not able to comply with the dosage regimen. * Subjects with immunodeficiencies. * Subjects with malignancy involving the bone marrow or lymphoid systems. * Pregnant or suspected pregnant women and breastfeeding women. * Subjects in medical treatment that affects the response of the immune system. It includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti TNF-alpha monoclonal antibodies, etc.). * Subjects with HIV. * Subjects under treatment with metformin. * Subjects treated with Sertraline. * Subjects treated with statins.